CYTK
Price
$65.60
Change
-$0.02 (-0.03%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
9.2B
27 days until earnings call
Intraday BUY SELL Signals
VRDN
Price
$19.43
Change
+$0.44 (+2.32%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
2.33B
45 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CYTK vs VRDN

CYTK vs VRDN Comparison Chart in %
View a ticker or compare two or three
VS
CYTK vs. VRDN commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and VRDN is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
CYTK vs VRDN: Fundamental Ratings
CYTK
VRDN
OUTLOOK RATING
1..100
8973
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
38
Fair valued
PROFIT vs RISK RATING
1..100
7282
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6056
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRDN's Valuation (38) in the Biotechnology industry is somewhat better than the same rating for CYTK (100). This means that VRDN’s stock grew somewhat faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (72) in the Biotechnology industry is in the same range as VRDN (82). This means that CYTK’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's SMR Rating (98) in the Biotechnology industry is in the same range as CYTK (100). This means that VRDN’s stock grew similarly to CYTK’s over the last 12 months.

VRDN's Price Growth Rating (56) in the Biotechnology industry is in the same range as CYTK (60). This means that VRDN’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for VRDN (100). This means that CYTK’s stock grew significantly faster than VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKVRDN
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 4 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 16 days ago
74%
N/A
Declines
ODDS (%)
Bearish Trend 8 days ago
78%
Bearish Trend 8 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (CYTK: $65.62 vs. VRDN: $18.99)
Brand notoriety: CYTK and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 83% vs. VRDN: 175%
Market capitalization -- CYTK: $9.2B vs. VRDN: $2.33B
CYTK [@Biotechnology] is valued at $9.2B. VRDN’s [@Biotechnology] market capitalization is $2.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green while VRDN’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, both CYTK and VRDN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 3 bullish TA indicator(s).

  • CYTK’s TA Score: 4 bullish, 4 bearish.
  • VRDN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than VRDN.

Price Growth

CYTK (@Biotechnology) experienced а -0.06% price change this week, while VRDN (@Biotechnology) price change was -8.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.58%. For the same industry, the average monthly price growth was -14.40%, and the average quarterly price growth was -1.79%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 29, 2026.

VRDN is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Biotechnology (-3.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CYTK
Daily Signal:
Gain/Loss:
VRDN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FPX180.091.91
+1.07%
First Trust US Equity Opportunities ETF (FPX)
QNXT30.970.15
+0.49%
iShares Nasdaq-100 ex Top 30 ETF (QNXT)
JHHY24.690.01
+0.04%
John Hancock High Yield ETF (JHHY)
CTWO19.02N/A
N/A
COtwo Advisors Physical European Carbon Allowance Trust ETF of Beneficial Interest (CTWO)
HAP72.81-0.29
-0.40%
VanEck Natural Resources ETF (HAP)

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with BBIO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then BBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-0.44%
BBIO - CYTK
42%
Loosely correlated
+1.69%
DARE - CYTK
42%
Loosely correlated
-0.27%
CRBU - CYTK
41%
Loosely correlated
-3.94%
NAMS - CYTK
40%
Loosely correlated
-0.66%
AXSM - CYTK
39%
Loosely correlated
-1.26%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with MLTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-7.77%
MLTX - VRDN
42%
Loosely correlated
-1.97%
CYTK - VRDN
40%
Loosely correlated
-0.44%
VCYT - VRDN
39%
Loosely correlated
-4.02%
RNA - VRDN
37%
Loosely correlated
-1.69%
AMLX - VRDN
36%
Loosely correlated
-3.51%
More